Boehringer and partners launch digital diabetes study
pharmafile | July 19, 2013 | News story | Medical Communications | Boehringer, Syrum, Twitter, diabetes, digital, type 2
Boehringer Ingelheim has partnered with Healthrageous and United BioSource to establish a new diabetes study to help patients manage their disease.
Private German firm Boehringer is well known for its pioneering digital approach to pharma, having already launched the industry’s first foray into gamification with ‘Syrum’, and also being an early proponent of Twitter.
This latest venture sees it team up with Healthrageous and United BioSource to evaluate a digital technology enabled self-management solution, to potentially improve the health status of people with type 2 diabetes.
Boehringer has a growing diabetes portfolio and is currently developing a new biosimilar, in conjunction with Lilly, for Sanofi’s insulin Lantus. It also co-markets the type 2 diabetes drug Trajenta with Lilly, which could reach blockbuster status.
The goal of this new digital programme is to “leverage technology in a way that makes the personalised journey of self-managing diabetes easier for patients to self-manage their disease,” according to Boehringer.
Healthrageous, a digital health management company, has launched the ‘SMART Study’ with Boehringer in partnership with United BioSource Corporation (UBC), a clinical services firm.
Under the scheme adults who have been diagnosed with type 2 diabetes for at least six months will have access to Healthrageous’ digital diabetes self-management programme, which is available on the internet and on smartphones.
It includes a personalised action plan with health behaviour improvement goals, a wireless glucose meter transmitting data to clinical monitors, as well home test kits to assess blood sugar levels.
By combining medical claims data, this collaboration aims to evaluate of the impact a digital diabetes platform could have on medical and pharma costs, clinical care, consumer behaviour and device and self-reported biometric health measures.
UBC will identify and help manage the recruitment of participants from nearly a dozen large US employers for the study.
“Boehringer Ingelheim is committed to innovation in diabetes treatment and strives for solutions that offer a ‘beyond pill’ approach in healthcare,” said Klaus Wilgenbus, SVP and PM, of business development at Boehringer.
“As part of our ongoing collaboration with Healthrageous, this project adds nicely to our goal to provide and develop solutions for patients and their families that contribute to a more holistic way of diabetes treatment.”
Abbe Steel, VP of patient and physician services at UBC, added: “Through a truly innovative, patient-centric design, this study will allow us to collect and integrate patient-reported data, biometric data and claims data in order to generate new insights into health behaviours, outcomes and cost utilisation.”
Ben Adams
Related Content
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Roche shares data on novel solution for continuous glucose monitoring
Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), …
Novo Nordisk shares positive results from COMBINE 3 phase 3a trial
Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly …
